Alogliptin
Alogliptin is a dipeptidyl peptidase-4 inhibitor used in type 2 diabetes. It prolongs incretin activity, supporting glucose-dependent insulin release.
Key points
- Alogliptin inhibits the DPP-4 enzyme.
- Its incretin effect is glucose-dependent and also reduces glucagon release.
Nesina is the catalogue’s single alogliptin identity for type 2 diabetes. Pancreatitis symptoms and heart-failure history receive specific attention in official information. Those clinical points distinguish alogliptin more usefully than restating each tablet strength.